Chronic obstructive pulmonary disease (COPD) Respiratory Other chronic obstructive pulmonary disease
Conditions
Interventions
On Day 1, 80 healthy subjects (54 males, 26 females) received either oral moxifloxacin 400 mg (as a positive control for prolongation of QT/heart-rate corrected QT [QTc]) (n = 40) or placebo (n = 40).
Principal Investigator)
2. Katherine L. Batiste (BS
sub-investigator)
3. Michael S. Benedict (BS
sub-investigator)
4. Katherine A. Day (BS
sub-investigator)
5. Dr David D Hoelscher (MD
sub-investigator)
6. Dr Laurent L Aziz (MD
sub-investigator)
Sponsors
Pfizer Global Research and Development (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects of any race were required to meet all of the following inclusion criteria to be eligible for enrolment into the study: 1. Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests [including magnesium]) 2. Body mass index (BMI) of approximately 18 to 30 kg/m2 and a total body weight >50 kg (110 lbs) 3. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) had been informed of all pertinent aspects of the trial 4. Subjects who were willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
Exclusion criteria
Exclusion criteria: 1. Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) 2. Subjects with any condition possibly affecting drug absorption (eg, gastrectomy) 3. Use of any medication not considered acceptable by the clinical investigators during the 14-day period prior to the start of the study (Day 1) 4. Blood donation of approximately 1 pint (500 mL) within 56 days prior to dosing 5. Participation in a study of investigational or marketed drugs during the 30-day period before the start of the study (Day 1) 6. Known history of clinically significant adverse reaction to roflumilast, moxifloxacin, or quinolone antibiotics 7. Use of any medication known to induce or inhibit CYP3A4 or CYP1A2 during the 14-day period prior to the start of study (Day 1) until Closeout 8. Use of any tobacco containing products during the 14-day period prior to the start of the study (Day 1) until Closeout 9. Use of St. John?s wort during the 14-day period prior to the start of the study (Day 1) until Closeout 10. Consumption of grapefruit juice or food products containing grapefruit during the 7-day period prior to the start of study (Day 1) until Closeout 11. Consumption of caffeine-containing products 48 hours prior to the start of the study (Day 1) until Closeout 12. Subjects with a positive urine drug screen 13. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for men (1 drink = 5 oz of wine or 12 oz [360 mL] of beer or 1.5 oz [45 mL] of hard liquor) within 6 months of screening 14. Pregnant or nursing females or females of childbearing potential who were unwilling or unable to use acceptable methods of contraception from at least 14 days prior to the first dose of trial medication until completion of follow-up procedures 15. History of sensitivity to heparin or heparin-induced thrombocytopenia 16. Evidence of hypomagnesemia 17. Clinically important or significant conduction abnormalities on ECG at Screening (including QTc intervals >430 msec for men or >450 msec for women) 18. Evidence or history of long QT syndrome 19. Subjects unwilling or unable to comply with the Lifestyle guidelines (Appendix A1, Final Protocol) and/or 20. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time-matched change from baseline in QTcF (Fridericia?s correction of the QT interval), calculated for each subject by subtracting the QTcF at each nominal time on the baseline day from the QTcF at the same nominal time on Days 1, 16 and 37. Comparisons between active drug and placebo were made using a repeated analysis of covariance, performed with a significance level of á = 0.05. Point estimates and their 90% confidence intervals (CI) were calculated. The primary treatment/placebo comparisons were roflumilast 500 µg with placebo on Day 16 and roflumilast 1000 µg with placebo on Day 37. The primary comparison between moxifloxacin and placebo for clinical interpretation was at the moxifloxacin anticipated tmax, approximately 2 hours post-dose on Day 1. Pharmacokinetic parameters were summarized using descriptive statistics; effect of roflumilast on RR using time-matched change from baseline day; and effect of roflumilast on QRS using time-matched change from baseline day. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Effect of roflumilast on QTcB (QT interval corrected by Bazett?s formula) using time-matched change from baseline day 2. Effect of roflumilast on QT (uncorrected QT interval) using time-matched change from baseline day 3. Effect of roflumilast on heart rate (VR) using time-matched change from baseline day 4. Effect of roflumilast on pulse rate using time-matched change from baseline day 5. Pharmacokinetics 6. Safety and tolerability | — |
Countries
United States of America
Outcome results
None listed